IRA Negotiated Drug Prices Released Free

Today, the U.S. government announced the final prices negotiated by Medicare under the 2022 Inflation Reduction Act (IRA) for 10 drugs, including one used to treat blood conditions, such as chronic lymphocytic leukemia and small lymphocytic lymphoma. The Bruton tyrosine kinase inhibitor ibrutinib (Imbruvica; AbbVie/Johnson & Johnson) has a list price of $14,934; the price negotiated between the drug-maker and Medicare will be $9,319—a 38% drop. When combined with cost cuts for the other agents—which treat a variety of conditions, such as diabetes and heart failure—the negotiated prices will save Medicare an estimated $6 billion. The new prices are set to take effect in 2026.